| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| iPSC-derived modeling of HLA-lacking hematopoiesis reveals clonal diversity in eltrombopag response in acquired aplastic anemia |
|
Stem Cells |
Aplastic Anemia |
| IPSS-M in myelodysplastic neoplasms arising from aplastic anemia and paroxysmal nocturnal hemoglobinuria |
|
Blood |
Aplastic Anemia |
| Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria |
|
Journal of Managed Care & Specialty Pharmacy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Expert Opinion on Pharmacotherapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes |
|
Annals of internal medicine |
Myelodysplastic Syndromes (MDS) |
| Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study |
|
Scientific Reports |
Myelodysplastic Syndromes (MDS) |
| Is blood transfusion safe during the COVID-19 pandemic? |
|
Future Science OA |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
